Show simple item record

dc.contributor.authorDomchek, S
dc.contributor.authorRobson, M
dc.contributor.authorIm, S
dc.contributor.authorSenkus, E
dc.contributor.authorXu, B
dc.contributor.authorMasuda, N
dc.contributor.authorDelaloge, S
dc.contributor.authorLi, W
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorConte, P
dc.contributor.authorBannister, W
dc.contributor.authorGoessl, C
dc.contributor.authorRunswick, S
dc.contributor.authorGoel, S
dc.contributor.authorTung, N
dc.date.accessioned2018-04-30T21:08:51Z
dc.date.available2018-04-30T21:08:51Z
dc.date.issued2018-02-14
dc.identifier.citationTolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. 2018, 78(4 Suppl): P5-21-12 Cancer Resen
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.doi10.1158/1538-7445.SABCS17-P5-21-12
dc.identifier.urihttp://hdl.handle.net/10541/620933
dc.language.isoenen
dc.relation.urlhttp://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS17-P5-21-12en
dc.rightsArchived with thanks to Cancer Researchen
dc.titleTolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentBasser Center, University of Pennsylvania, Philadelphia, PAen
dc.identifier.journalCancer Researchen


This item appears in the following Collection(s)

Show simple item record